Gene Therapy Updates for Inherited Retinal Dystrophies

Authors

  • Melissa Lu, MD Department of Ophthalmology, University of Montreal, Montreal, Quebec Department of Ophthalmology, Hôpital Maisonneuve-Rosemont, Montreal, Quebec
  • Daniel Milad, MD Department of Ophthalmology, University of Montreal, Montreal, Quebec Department of Ophthalmology, Hôpital Maisonneuve-Rosemont, Montreal, Quebec
  • Cynthia X. Qian, MD, FRCSC Department of Ophthalmology, University of Montreal, Montreal, Quebec Department of Ophthalmology, Hôpital Maisonneuve-Rosemont, Montreal, Quebec Department of Ophthalmology, Hôpital Sainte-Justine, Montreal, Quebec

Abstract

Inherited retinal dystrophies (IRDs) encompass a group of genetically diverse disorders, each uniquely influencing distinct retinal cell pathways and retinal areas. IRDs currently affect an estimated 5.5 million individuals worldwide, exerting a profound impact on the quality of life of those affected. Depending on the mutated gene, typical presentations often manifest as colour or night blindness, or peripheral vision blindness progressing to complete blindness. Consequently, patients grappling with IRDs face not only the physical challenges of their condition, but also endure significant psychosocial and economic repercussions.

Author Biographies

Melissa Lu, MD , Department of Ophthalmology, University of Montreal, Montreal, Quebec Department of Ophthalmology, Hôpital Maisonneuve-Rosemont, Montreal, Quebec

Dr. Melissa Lu is currently a first-year ophthalmology resident at the University of Montreal, where she also obtained her medical degree.

Daniel Milad, MD, Department of Ophthalmology, University of Montreal, Montreal, Quebec Department of Ophthalmology, Hôpital Maisonneuve-Rosemont, Montreal, Quebec

Dr. Daniel Milad is a third-year ophthalmology resident at the University of Montreal in Montreal, Canada. Dr. Milad completed his medical degree at Laval University. His research interests are centered around the integration of new technologies in ophthalmology, with a particular focus on the application of artificial intelligence and extended reality in vitreoretinal surgical and medical conditions. His work was recognized at the University of Montreal’s 34th Ophthalmology Research Day with the Roch Gagnon Podium Presentation award and at the 2023 Retina Case Conference Canada with the Best Medical Retina Presentation award. Dr. Milad’s academic contributions, including several publications and reviews in peer-reviewed journals, reflect his dedication to the evolving landscape of ophthalmological practice and research.

Cynthia X. Qian, MD, FRCSC, Department of Ophthalmology, University of Montreal, Montreal, Quebec Department of Ophthalmology, Hôpital Maisonneuve-Rosemont, Montreal, Quebec Department of Ophthalmology, Hôpital Sainte-Justine, Montreal, Quebec

Dr. Cynthia X. Qian is an Associate Professor in the Department of Ophthalmology at the University of Montreal, where she is also Chief of the Retina Service. She is the Vice President of the Canadian Retina Society, the chair of Royal College Retina AFC Committee, and the CPD Council Chair for the Canadian Ophthalmological Society. As an FRQS clinical research scholar, her research focuses on pediatric retinal diseases, therapies in inherited retinal diseases, and clinical trials in age-related macular degeneration and diabetic retinopathy. Cynthia has garnered notable accolades beyond her contributions to academia,. In 2018, she was honoured as “The Young Professional of the Year” by the Young Chamber of Commerce of Montreal. In 2019, she was recognized as one of Canada’s Top 40 under 40, and in 2021, she earned distinction as one of the top 5 early-career physicians of the year by the Collège des Médecins.

References

Ben-Yosef T. Inherited retinal diseases. Int J Mol Sci. 2022 Nov 3;23(21):13467.

Chawla H, Vohra V. Retinal Dystrophies. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2024 Jan 8]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK564379/

Gong J, Cheung S, Fasso-Opie A et al. The impact of inherited retinal diseases in the United States of America (US) and Canada from a cost-of-illness perspective. Clin Ophthalmol Auckl NZ. 2021 Jul 1;15:2855–66.

Drag S, Dotiwala F, Upadhyay AK. Gene therapy for retinal degenerative diseases: progress, challenges, and future directions. Invest Ophthalmol Vis Sci. 2023 Jun 1;64(7):39.

Kansara V, Muya L, Wan CR, et al. Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases. J Ocul Pharmacol Ther. 2020;36(6):384–92.

Lipinski DM, Thake M, MacLaren RE. Clinical applications of retinal gene therapy. Prog Retin Eye Res. 2013 Jan;32:22‑47.

Wang L, Shah SM, Mangwani-Mordani S et al. Updates on emerging interventions for autosomal recessive ABCA4-associated Stargardt disease. J Clin Med. 2023 Sep 27;12(19):6229.

Tsang SH, Sharma T. Best vitelliform macular dystrophy. Adv Exp Med Biol. 2018;1085:79–90.

Tripathy K, Salini B. Best Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2024 Jan 8]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK537290/

Ku CA, Wei LW, Sieving PA. X-linked retinoschisis. Cold Spring Harb Perspect Med. 2023 Sep 1;13(9):a041288.

Michalakis S, Gerhardt M, Rudolph G et al. Achromatopsia: genetics and gene therapy. Mol Diagn Ther. 2022;26(1):51–9.

Fischer MD, Michalakis S, Wilhelm B et al. Safety and vision outcomes of subretinal gene therapy targeting cone photoreceptors in achromatopsia: a nonrandomized controlled trial. JAMA Ophthalmol. 2020 Jun 1;138(6):643‑51.

Verbakel SK, van Huet RAC, Boon CJF et al. Non‑syndromic retinitis pigmentosa. Prog Retin Eye Res. 2018 Sep;66:157‑86.

Newswire MP. Late-Breaking 12-Month Data of RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with X-Linked Retinitis Pigmentosa [Internet]. MultiVu. [cited 2024 Jan 8]. Available from: https://www.multivu.com/players/English/8798151-janssen-rpgr-gene-therapy-data-in-patients-with-x-linked-retinitis-pigmentosa/

ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials | ProQR Therapeutics [Internet]. [cited 2024 Jan 8]. Available from: https://www.proqr.com/press-releases/proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plans-to-start-pivotal-trials

Nuzbrokh Y, Ragi SD, Tsang SH. Gene therapy for inherited retinal diseases. Ann Transl Med. 2021 Aug;9(15):1278.

Chacon-Camacho OF, Zenteno JC. Review and update on the molecular basis of Leber congenital amaurosis. World J Clin Cases WJCC. 2015 Feb 16;3(2):112–24.

Qian CX, Rezende FA. Surgical technique enhancements for successful subretinal gene therapy delivery. Can J Ophthalmol [Internet]. 2023 Oct 23 [cited 2024 Jan 8];0(0). Available from: https://www.canadianjournalofophthalmology.ca/article/S0008-4182(23)00309-5/fulltext

Deng C, Zhao PY, Branham K et al. Real-world outcomes of voretigene neparvoyec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis. Graefes Arch Clin Exp Ophthalmol. 2022 May;260(5):1543–50.

Russell SR, Drack AV, Cideciyan AV et al. Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial. Nat Med. 2022;28(5):1014–21.

Home | ClinicalTrials.gov [Internet]. [cited 2024 Jan 8]. Available from: https://www.clinicaltrials.gov/

Lam BL, Davis JL, Gregori NZ. Choroideremia gene therapy. Int Ophthalmol Clin. 2021;61(4):185–93.

Abdalla Elsayed MEA, Taylor LJ, Josan AS et al. Choroideremia: the endpoint endgame. Int J Mol Sci. 2023 Sep 20;24(18):14354.

Downloads

Published

2024-02-28

How to Cite

1.
Lu M, Milad D, Qian CX. Gene Therapy Updates for Inherited Retinal Dystrophies. Can Eye Care Today [Internet]. 2024 Feb. 28 [cited 2024 May 1];3(1):4–11. Available from: https://canadianeyecaretoday.com/article/view/3-1-lu_et_al

Issue

Volume 3, Issue 1, February 2024

Section

Articles

License

Copyright (c) 2024 Canadian Eye Care Today

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.